Readers will be pleased to learn this is the final installment of my reviews of the HBO Chernobyl miniseries, which just ended its TV run June 3. The series, which has received extraordinary critical acclaim, had a vast global audience.
Last December, Flatiron Health convened a “hackathon,” an event where programmers, developers, and scientists pitch novel ideas and aggressively crunch data in a competitive sprint.
The Cancer Letter won four 2019 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists:
FDA granted accelerated approval to Polivy (polatuzumab vedotin-piiq), a novel antibody-drug conjugate, in combination with the chemotherapy bendamustine and rituximab product, to treat adult patients with diffuse large B-cell lymphoma that has progressed or returned after at least two prior therapies.
FDA has approved Merck's Keytruda as monotherapy in patients whose tumors express PD-L1 (Combined Positive Score ≥1) or in combination with platinum and fluorouracil for the first-line treatment of patients with metastatic or unresectable, recurrent head and neck squamous cell carcinoma.
FDA has approved Agilent Technologies Inc.'s PD-L1 IHC 22C3 pharmDx assay for expanded use.
Cofactor Genomics said it has become a member of the Foundation for NIH Biomarkers Consortium with the goal of advancing the adoption of multidimensional biomarkers in cancer and immune-related diseases.
There were more than 16.9 million Americans with a history of cancer on Jan. 1, 2019. The number is projected to reach more than 22.1 million by 2030 based on the growth and aging of the population alone, according to estimates from Cancer Treatment and Survivorship Statistics, 2019.
Researchers at the USC Norris Comprehensive Cancer Center found identifying a metastatic colorectal cancer patient's Consensus Molecular Subtype could help oncologists determine the most effective course of treatment. CMS also had prognostic value, meaning each subgroup was indicative of a patient's overall survival, regardless of therapy.
Study suggests higher triple-negative breast cancer incidence among black women is not generalizable
A new study found substantial variation in the prevalence of triple-negative breast cancer among black women with breast cancer by birthplace in the U.S.
